Netupitant/Palonosetron [Akynzeo] for nausea and vomiting associated with cancer chemotherapy approved in the US

Last Updated on

October 12, 2014 – The U.S. Food and Drug Administration, on October 10,  approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy. Akynzeo is a fixed combination capsule comprised of two drugs. Oral palonosetron approved in 2008 as Aloxi, prevents nausea and vomiting during the acute phase (within the first 24 hours) after the start of cancer chemotherapy. Netupitant, a new drug, prevents nausea and vomiting during both the acute phase and delayed phase (from 25 to 120 hours) after the start of cancer chemotherapy.

Netupitant

Netupitant

“Supportive care products, such as Akynzeo, help ease the nausea and vomiting patients may experience as a side effect of cancer chemotherapy,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. Akynzeo’s effectiveness was established in two clinical trials of 1,720 participants receiving cancer chemotherapy. Participants were randomly assigned to receive Akynzeo or oral palonosetron. The trials were designed to measure whether the study drugs prevented any vomiting episodes in the acute, delayed and overall phases after the start of cancer chemotherapy.

Results of the first trial showed that 98.5 percent, 90.4 percent and 89.6 percent of Akynzeo-treated participants did not experience any vomiting or require rescue medication for nausea during the acute, delayed and overall phases, respectively. In contrast, 89.7 percent, 80.1 percent and 76.5 percent of participants treated with oral palonosetron did not experience any vomiting or require rescue medication for nausea during the acute, delayed and overall phases, respectively. The second trial showed similar results. Common side effects of Akynzeo in the clinical trials were headache, weakness (asthenia), fatigue, indigestion (dyspepsia) and constipation.

Tags: , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.
1 Pings/Trackbacks for "Netupitant/Palonosetron [Akynzeo] for nausea and vomiting associated with cancer chemotherapy approved in the US"

Your opinion

Comment

No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Mayo researchers recommend all women with breast cancer diagnosis under age 66 be offered genetic testing February 21, 2020
    A study by researchers at Mayo Clinic published this week in the Journal of Clinical Oncology suggests that all women with a breast cancer diagnosis under the age of 66 be offered germline genetic testing to determine if they have a gene mutation known to increase the risk of developing other cancers and cancers among […]
  • Cross-talk between enzymes that read and correct recipes in the cookbook of life February 21, 2020
    DNA is the hereditary material in humans, a unique cookbook of who we are. This is where you'll find the answer as to why you have your specific eye and hair colour, or perhaps why you sunburn easily.
  • Study finds certain genetic tests not useful in predicting heart disease risk February 21, 2020
    A Polygenic Risk Score—a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients—has been found not to be a useful predictive biomarker for disease risk, according to a Vanderbilt study published in the Journal of the American Medical Association.
  • Major discovery in the genetics of Down syndrome February 21, 2020
    Researchers at CHU Sainte-Justine and Université de Montréal have discovered a new mechanism involved in the expression of Down syndrome, one of the main causes of intellectual disability and congenital heart defects in children. The study's findings were published today in Current Biology.
  • MicroRNA exhibit unexpected function in driving cancer February 20, 2020
    Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer. New research from Thomas Jefferson University has revealed that both strands of some microRNA coordinate to act on […]
  • Ethnobotanical medicine is effective against the bacterium causing Lyme disease February 21, 2020
    A preclinical in vitro study shows that selected plant-based herbal medicines, especially Ghanaian quinine and Japanese knotweed, work better than antibiotics against the bacterium that causes Lyme disease. These findings represent an important step towards the development of treatments that might be better tolerated and more effective than the current standard of care.
  • Opportunity blows for offshore wind in China February 21, 2020
    If China is to meet and exceed its Paris Climate Agreement goal by 2030, it's going to need to find a way to increase its wind capacity. Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and Huazhong University of Science and Technology in China, found that offshore wind could […]
  • Alcohol-induced deaths in US February 21, 2020
    National vital statistics data from 2000 to 2016 were used to examine how rates of alcohol-induced deaths (defined as those deaths due to alcohol consumption that could be avoided if alcohol weren't involved) have changed in the US and to compare the results by demographic groups including sex, race/ethnicity, age, socioeconomic status and geographic location. […]
  • The integrated catalysts can simplify pharmaceutical manufacturing February 21, 2020
    Prof. In Su Lee and his research team from POSTECH developed catalytic platforms based on metal organic frameworks.
  • Shaping the rings of molecules February 21, 2020
    Canadian chemists discover a natural process to control the shape of 'macrocycles,' molecules of large rings of atoms, for use in pharmaceuticals and electronics.
Top